Skip to content

Study · Animal study (in vivo) · rat · 2018

7 results

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.

Boulete IM, Thadi A, Beaufrand C, Patwa V, Joshi A, Foss JA, Eddy EP, Eutamene H, Palejwala VA, Theodorou V, Shailubhai K

World journal of gastroenterology1 May 2018Cited by 25 (Europe PMC)

PMID29740204 (opens in a new tab)PMCIDPMC5937206 (opens in a new tab)DOI10.3748/wjg.v24.i17.1888 (opens in a new tab)PepBankPUB-29740204
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, plecanatide suppressed the TNBS-induced increase in abdominal contractions during colorectal distension.

    In plain wordsIn rats, plecanatide reduced TNBS-induced abdominal contractions during colorectal distension.

    Peptide
    Plecanatide
    Outcome
    DecreaseAbdominal contractions after colorectal distension
    Study

    ratn: not reported in source

    TNBS-induced visceral hypersensitivity
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    In rat visceral hypersensitivity models, both agonists suppressed the TNBS-induced increase in abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity, and both agonists also reduced colonic hypersensitivity in the PRS model.
    2 context sentences
    Summary · context
    Anti-nociceptive activity of these agonists was evaluated in trinitrobenzene sulfonic acid (TNBS)-induced inflammatory as well as in non-inflammatory partial restraint stress (PRS) rat models.
    Title · context
    Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced visceral hypersensitivity, plecanatide did not affect colonic wall elasticity.

    In plain wordsIn rats with TNBS-induced gut sensitivity, plecanatide did not affect colon wall elasticity.

    Peptide
    Plecanatide
    Outcome
    No significant changeColonic wall elasticity
    Study

    ratn: not reported in source

    TNBS-induced visceral hypersensitivity
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    In rat visceral hypersensitivity models, both agonists suppressed the TNBS-induced increase in abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity, and both agonists also reduced colonic hypersensitivity in the PRS model.
    2 context sentences
    Summary · context
    Anti-nociceptive activity of these agonists was evaluated in trinitrobenzene sulfonic acid (TNBS)-induced inflammatory as well as in non-inflammatory partial restraint stress (PRS) rat models.
    Title · context
    Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, plecanatide reduced colonic hypersensitivity in the partial restraint stress model.

    In plain wordsIn rats, plecanatide reduced colon sensitivity in the partial restraint stress model.

    Peptide
    Plecanatide
    Outcome
    DecreaseColonic hypersensitivity
    Study

    ratn: not reported in source

    Partial restraint stress visceral hypersensitivity
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    In rat visceral hypersensitivity models, both agonists suppressed the TNBS-induced increase in abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity, and both agonists also reduced colonic hypersensitivity in the PRS model.
    2 context sentences
    Summary · context
    Anti-nociceptive activity of these agonists was evaluated in trinitrobenzene sulfonic acid (TNBS)-induced inflammatory as well as in non-inflammatory partial restraint stress (PRS) rat models.
    Title · context
    Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.
  4. 04LabIn vitro (cells)Efficacy outcome

    In T84 and Caco-2 cells, plecanatide suppressed the LPS-induced increase in permeability versus LPS alone.

    In plain wordsIn cells, plecanatide reduced LPS-induced leakage versus LPS alone.

    Peptide
    Plecanatide
    Outcome
    DecreaseParacellular permeability after LPS
    Study

    n: not reported in source

    T84 and Caco-2 monolayers exposed to LPS
    Comparator
    LPS alone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of T84 and Caco-2 monolayers with lipopolysaccharide (LPS) rapidly increased permeability, which was effectively suppressed when monolayers were also treated with plecanatide or dolcanatide.
    1 context sentence
    Summary · context
    Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy.
  5. 05LabIn vitro (cells)Mechanism

    In LPS-treated cell monolayers, plecanatide preserved cell-surface occludin localization similar to vehicle-treated cells.

    In plain wordsIn cells exposed to LPS, plecanatide preserved surface occludin localization similar to vehicle-treated cells.

    Peptide
    Plecanatide
    Outcome
    Not applicableOccludin localization after LPS
    Study

    n: not reported in source

    T84 and Caco-2 monolayers exposed to LPS
    Comparator
    Vehicle-treated cells
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When cell monolayers were treated with LPS in the presence of plecanatide or dolcanatide, occludin and ZO-1 were localized at the cell surface of adjoining cells, similar to that observed for vehicle treated cells.
    1 context sentence
    Summary · context
    Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy.
  6. 06LabIn vitro (cells)Mechanism

    In LPS-treated cell monolayers, plecanatide preserved cell-surface ZO-1 localization similar to vehicle-treated cells.

    In plain wordsIn cells exposed to LPS, plecanatide preserved surface ZO-1 localization similar to vehicle-treated cells.

    Peptide
    Plecanatide
    Outcome
    Not applicableZO-1 localization after LPS
    Study

    n: not reported in source

    T84 and Caco-2 monolayers exposed to LPS
    Comparator
    Vehicle-treated cells
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When cell monolayers were treated with LPS in the presence of plecanatide or dolcanatide, occludin and ZO-1 were localized at the cell surface of adjoining cells, similar to that observed for vehicle treated cells.
    1 context sentence
    Summary · context
    Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy.
  7. 07LabIn vitro (cells)Efficacy outcome

    In cell monolayers without LPS, plecanatide did not alter permeability, tight junction integrity, or cell-surface localization of occludin and ZO-1.

    In plain wordsIn cells without LPS, plecanatide did not alter permeability, tight junction integrity, or localization of the two junction proteins.

    Peptide
    Plecanatide
    Outcome
    No significant changeBarrier properties without LPS
    Study

    n: not reported in source

    T84 and Caco-2 monolayers without LPS
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of cell monolayers with plecanatide or dolcanatide without LPS did not alter permeability, integrity of tight junctions and cell surface localization of either of the tight junction proteins.
    1 context sentence
    Summary · context
    Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.